Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/39052
Title: | Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS | Authors: | Kalincik, T. Sharman, S. Roos, I. Freedman, M. Atkins, H. Burman, J. Massey, J. Sutton, I. Withers, B. Macdonell, R. Grigg, A. Torkildsen, O. Bo, L. Lehmann, A. Horakova, D. Havrdova, E. Krasulova, E. Trneny, M. Kozak, T. van der Walt, A. Butzkueven, H. McCombe, P. VAN WIJMEERSCH, Bart Buzzard, K. Skibina, O. Lechner-Scott, J. Willekens, B. Barnett, M. Cartechini, E. Ozakbas, S. Alroughani, R. Izquierdo, G. Eichau, S. Boz, C. Kuhle, J. Patti, F. Terzi, M. Prat, A. Girard, M. Duquette, P. Grammond, P. Onofrj, M. Lugaresi, A. Khoury, S. Soysal, A. Slee, M. Prevost, J. Turkoglu, R. Sharrack, B. Snowden, J. |
Issue Date: | 2022 | Publisher: | SAGE PUBLICATIONS LTD | Source: | Multiple Sclerosis Journal, 28 (S3) , p. 11 -14 | Abstract: | Oral Presentations 28 (3S) 11 journals.sagepub.com/home/msj Multiple Sclerosis Journal 2022; 28: (3S) 3-129 probability of relapse in glatiramer acetate (OR=27.27; 95%CI= 9.15,81.29; p<0.01), dimethyl-fumarate (OR=10.60; 95%CI= 3.49,32.17; p<0.01), fingolimod (OR=16.28; 95%CI=5.35,49.52; p<0.01), and natalizumab (OR=17.20; 95%CI=5.66,52.29; p<0.01), compared with ocrelizumab. EDSS more likely increased in glatiramer acetate (OR=1.34; 95%CI=1.19,1.51; p<0.01), dimethyl-fumarate (OR=1.26; 95%CI=1.12,1.43; p<0.01), fingolimod (OR=1.59; 95%CI=1.41,1.80; p<0.01), and natalizumab (OR=1.86; 95%CI=1.63,2.12; p<0.01), compared with ocrelizumab. The probability of new/Gd-enhancing lesions was higher in glatiramer acetate (OR=4.02; 95%CI =1.74,9.27; p<0.01), compared with ocrelizumab, while no differences were found for dimethyl-fumarate (p=0.42), fingoli-mod (p=0.87), and natalizumab (p=0.11). On propensity score-adjusted Cox regression models, NEDA-3 status was achieved by 90.23% of patients treated with ocrelizumab, and, less so, glati-ramer acetate (44.24%; HR=12.52; 95%CI=9.55,16.42; p<0.01), dimethyl-fumarate (62.08%; HR=1.66; 95%CI=1.30,2.11; p<0.01), fingolimod (54.16%; HR=2.98; 95%CI=2.35,3.77; p<0.01), and natalizumab (57.72%; HR=1.71; 95%CI=1.32,2.21; p<0.01). Discussion: Ocrelizumab proved superior to other DMTs in achieving NEDA-3 status and reducing EDSS worsening, using propensity score adjustment. The less striking results on MRI lesions could be due to the limited sample size analysed. Further analyses on more MRI outcomes and in a larger group of patients is ongoing. | Document URI: | http://hdl.handle.net/1942/39052 | ISSN: | 1352-4585 | e-ISSN: | 1477-0970 | ISI #: | 000866540800020 | Category: | M | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Comparative effectiveness of autologous haematopoietic.pdf | Published version | 70.78 kB | Adobe PDF | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.